[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356811-105":59,"doc-detail-356811-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","cxcl16-driven-cd4-t-cells-orchestrate-immunosurveillance-against-mhc-i-deficient-hepatocellular-tumors","CXCL16-driven CD4+ T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors","","Major histocompatibility complex class I (MHC-I) loss is a common tumor immune-evasion strategy, yet its impact on the tumor microenvironment and immune-cell coordination remains unclear. Using CRISPR/Cas9 to generate B2m knockout MHC-I-deficient tumor cells, the study tests growth in mouse models and profiles immune populations by flow cytometry and single-cell RNA sequencing. CD4+ T cells, NK cells, and macrophages mediate suppression of MHC-I-deficient hepatocellular tumors, driven by CXCL16 context-dependent regulation.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cxcl16-driven-cd4-t-cells-orchestrate-immunosurveillance-against-mhc-i-deficient-hepatocellular-tumors/356811/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cxcl16-driven-cd4-t-cells-orchestrate-immunosurveillance-against-mhc-i-deficient-hepatocellular-tumors/356811.png","ImageObject",300,407,{"name":92,"@type":93},"Nguyễn Văn Học","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does this study address about MHC-I loss?","Question",{"text":113,"@type":114},"It addresses how loss of MHC-I shapes the tumor microenvironment and alters immune-cell interactions that influence tumor growth and immune control.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were MHC-I-deficient tumors generated and evaluated?",{"text":118,"@type":114},"B2m knockout tumor cells were created using CRISPR/Cas9, then tumor growth was assessed in subcutaneous and orthotopic mouse models with immune profiling by flow cytometry and single-cell RNA sequencing.",{"name":120,"@type":111,"acceptedAnswer":121},"What role do CD4+ T cells play in suppressing MHC-I-deficient hepatocellular tumors?",{"text":122,"@type":114},"CD4+ T cells are required to recruit NK cells and monocytes/macrophages and to induce tumoricidal macrophage phenotypes, including iNOS expression.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356811,1790302827,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":36,"preview_page_count":19,"preview_urls":146},1374402739827,"https://ap-avatar.wpscdn.com/avatar/14000c97e7351f1a627?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787885694763230660","Open access  \nTo cite: Zhou Y, Chen P, Wang Z, et al. CXCL16-driven CD4+ T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors. Journal for ImmunoTherapy of Cancer 2026;14:e012347 . doi:10 . 1136/ jitc-2025-012347  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-012347](jitc-2025-012347)) .  \nYZ and PC contributed equally. Accepted 30 April 2026  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Shanghai Key Laboratory for Cancer System Regulation and Clinical Translation, Jiading District Central Hospital Affiliated Shanghai University of Medicine & Health Sciences, Shanghai, China  \n2School of Biomedical Engineering, Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China 3State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute,  \nShanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China 4Chongqing Research Institute, Shanghai Jiao Tong University, Chongqing, China  \nCorrespondence to  \nDr Bin Ma; [bin.ma@outlook.com](bin.ma@outlook.com)  \nOriginal research  \nCXCL16-driven CD4 + T cells orchestrate immunosurveillance against  \nMHC-I-deficient hepatocellular tumors  \nYunyi Zhou,1,2 Ping Chen,1 Zhixue Wang,1,2 Liming Gui,1 Zhengheng Zheng,1,2 Wei-Qiang Gao,2,3 Bin Ma  1,4  \nABSTRACT  \nBackground Major histocompatibility complex class I (MHC)-I loss is a prevalent mechanism for immune evasion and resistance to immunotherapy. However, how MHC-I loss shapes the tumor microenvironment and influences immune cell interactions, ultimately affecting tumor growth, remains largely unknown.  \nMethods We established B2m knockout (MHC-I-deficient) tumor cells using CRISPR/Cas9 and evaluated their growth in subcutaneous and orthotopic mouse models. Immune profiling was performed using flow cytometry and single-cell RNA sequencing. Antibody-mediated cell depletion was used to assess the functional contributions of specific immune subsets. Chemokine expression was analyzed by bulk RNA sequencing, quantitative PCR, ELISA and western blotting, and its functional relevance was determined using knockout or overexpression in tumor cells implanted in vivo. Signaling pathways were interrogated using pharmacological inhibition, RNA interference and western blotting.  \nResults MHC-I loss promoted tumor growth in MC38, AKR, and LLC1 models, but unexpectedly suppressed Hepa1-6 and orthotopic MYC;Trp53−/− hepatocarcinoma growth. This differential effect correlated with changes in immune infiltrates. CD4+ T cells, natural killer (NK) cells, and macrophages were required for suppression of MHC-I-deficient Hepa1-6 tumors. CD4+ T cells  \nwere essential for recruiting NK cells and monocytes/ macrophages and for inducing their tumoricidal phenotypes, including iNOS (inducible nitric oxide synthase) expression in macrophages. The differential infiltration of CD4+ T cells was driven by opposite regulation of CXCL16 on B2m knockout: upregulation in Hepa1-6 cells and downregulation in other models. CXCL16 exerted potent antitumor effects by recruiting CD4+ T cells. Mechanistically, B2M loss regulated CXCL16 via suppression of Akt in MC38 and AKR cells, but via activation of NF-κB in Hepa1-6 cells.  \nConclusion CXCL16-driven CD4+ T cells are central regulators of antitumor immunity against MHC-I-deficient tumors. The context-dependent regulation of CXCL16 by MHC-I loss determines the immune landscape and tumor outcome, highlighting a potential therapeutic avenue for targeting MHC-I-deficient cancers.  \nBACKGROUND  \nAntigens presented through major histocompatibility complex class I (MHC-I) are  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ Major histocompatibility complex class I (MHC)-I loss is a common mech","cbCaiqQigC4o5gwk","https://ap.wps.com/l/cbCaiqQigC4o5gwk","pdf",9363637,16,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusion\n# Background\n## MHC-I loss and immune recognition","[{\"question\":\"What problem does this study address about MHC-I loss?\",\"answer\":\"It addresses how loss of MHC-I shapes the tumor microenvironment and alters immune-cell interactions that influence tumor growth and immune control.\"},{\"question\":\"How were MHC-I-deficient tumors generated and evaluated?\",\"answer\":\"B2m knockout tumor cells were created using CRISPR/Cas9, then tumor growth was assessed in subcutaneous and orthotopic mouse models with immune profiling by flow cytometry and single-cell RNA sequencing.\"},{\"question\":\"What role do CD4+ T cells play in suppressing MHC-I-deficient hepatocellular tumors?\",\"answer\":\"CD4+ T cells are required to recruit NK cells and monocytes/macrophages and to induce tumoricidal macrophage phenotypes, including iNOS expression.\"}]","CXCL16-driven CD4+ T cells orchestrate immunosurveillance against MHC-I-deficient hepatocellular tumors | PDF",1790127431,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a84ad63a8144f5d2e974cfc93191f393.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/12336a62cacc5d130c99112bbcca8d84.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d45d3274d05df38a19d46b71ef463c4.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/314e6b6007e41cec83a95f7bb09a753c.webp",980,1306]